MedPath

SINAI HEALTH SYSTEM

🇺🇸United States
Ownership
-
Established
2015-01-01
Employees
-
Market Cap
-
Website
http://www.sinaihealthsystem.ca/

Clinical Trials

4

Active:1
Completed:1

Trial Phases

1 Phases

Not Applicable:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Not Applicable
4 (100.0%)

Improving Diabetes Equity and Advancing Care Study

Not Applicable
Recruiting
Conditions
Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes
First Posted Date
2023-09-15
Last Posted Date
2023-12-07
Lead Sponsor
Sinai Health System
Target Recruit Count
270
Registration Number
NCT06040463
Locations
🇺🇸

Mount Sinai Hospital, Chicago, Illinois, United States

Helping Chicago's Westside Adults Breathe and Thrive

Not Applicable
Conditions
Asthma
First Posted Date
2018-04-05
Last Posted Date
2018-04-05
Lead Sponsor
Sinai Health System
Target Recruit Count
143
Registration Number
NCT03489655
Locations
🇺🇸

Mount Sinai Hospital, Chicago, Illinois, United States

Controlling Hyperglycemia Among Minority Population

Not Applicable
Completed
Conditions
Diabetes
First Posted Date
2016-02-12
Last Posted Date
2018-01-26
Lead Sponsor
Sinai Health System
Target Recruit Count
272
Registration Number
NCT02681718
Locations
🇺🇸

Mount Sinai Hospital, Chicago, Illinois, United States

News

Abbott's Groundbreaking AVEIR Leadless Pacemaker Shows Promise in First-in-Human Conduction System Pacing Study

Abbott's AVEIR Conduction System Pacing leadless pacemaker demonstrated successful implantation in the left bundle branch area of the heart in a first-of-its-kind feasibility study presented at HRS 2025.

BTL's Novel Catheter Shows Promise in Early Atrial Fibrillation Ablation

• BTL announced successful treatment of initial patients in a first-in-human study using a next-generation catheter for atrial fibrillation (AF) ablation. • The catheter system employs pulsed-field ablation (PFA) to enhance the safety, speed, and effectiveness of AF treatments. • Early results from six patients indicate the new catheter is safe, effective, and straightforward, aligning with preclinical study outcomes. • The novel catheter features single-shot pulmonary vein isolation (PVI) and is designed for intuitive placement, improving procedural reliability.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.